Preface

This summary addresses biomaterial scaffolds: porous polymers, hydrogels, decellularised matrices and 3D-bioprinted constructs, used alone or combined with cells (e.g. mesenchymal stromal cells [MSCs], chondrocytes) or signalling molecules, intended to regenerate or replace damaged tissue. The honest headline is that robust, high-certainty human evidence exists for only a narrow set of localised, structural applications (chondral defects, chronic/burn wounds, periodontal/bone defects), while all systemic anti-ageing or “rejuvenation” uses of scaffolds remain preclinical or mechanistic only, with no supportive human outcome data.[1][2][3]


1. Scope

– Covered: The clinical role, evidence base, patient selection, practical delivery and safety of scaffold-based tissue engineering as it may present in a UK longevity/regenerative clinic — chiefly as adjunctive care alongside conventional primary/secondary services.

– Best-evidenced indications: focal articular cartilage repair (MACI/ACI); chronic and burn wounds / dermal regeneration; periodontal and peri-implant/bone defect reconstruction.[4][5][6][7][8][9][10][11][12]

– Not covered in depth (and explicitly flagged experimental): whole-organ engineering, tissue-engineered airways/trachea, bioprinted organs, and any “systemic” scaffold-based ageing reversal. These are research-only or compassionate-use and, in the case of synthetic tracheal grafts, associated with catastrophic outcomes and research misconduct.[13][14][15]

– Not a substitute for licensed surgical/orthopaedic, dermatological or dental pathways where those exist.



2. Background and pathophysiology

– Biological rationale: Regenerative capacity declines with age. Scaffolds aim to reconstitute a functional extracellular-matrix (ECM) niche — providing mechanical support and cues for cell attachment, migration, proliferation and differentiation — to bridge defects that native tissue cannot self-repair (e.g. hyaline cartilage).[16][17][7]

– Mechanisms targeted (in ageing-relevant tissues): restoration of ECM architecture; delivery/retention of reparative cells; modulation of the local inflammatory/senescent microenvironment; promotion of angiogenesis and re-epithelialisation.[1][18]

– Robust human mechanistic evidence: Confined to local structural repair. In cartilage, MACI produces durable defect fill and repair tissue on MRI/histology with correlated clinical improvement. In wounds, dermal templates support fibrovascular ingrowth and re-epithelialisation.[5][19][8][9]

Preclinical only (mechanistic plausibility, no human outcome data): MSC-senescence “rejuvenation” via biomaterial stiffness/topography cues; ROS-scavenging Mg/Ce metal-organic-framework bioprinted scaffolds improving the senescent microenvironment in aged rodent bone defects; biomaterial modulation of autophagy, telomere protection and epigenetic pathways in osteoarthritis.[1][2][3][18] These should not be presented to patients as clinically validated anti-ageing therapies.



3. Evidence base and grading

Study types available: Level 1 RCTs and long-term systematic reviews for cartilage; a large systematic review of 128 RCTs for periodontal/peri-implant applications; a PRISMA/GRADE systematic review for MSC-in-scaffold bone regeneration; systematic reviews/cohorts for skin substitutes.[4][5][6][7][19][12][11][8][10][9] Higher-order longevity outcomes (mortality, healthspan, validated ageing biomarkers) have not been studied for any scaffold therapy.

Outcome / indication	Evidence statement	GRADE certainty	Strength of recommendation	Key limitations
Cartilage repair — MACI vs microfracture (pain/function, structural fill, defect ≥3 cm²)	Multiple Level 1 RCTs (SUMMIT n=144; 6-yr RCT) + 10-yr systematic review show durable KOOS gains, low failure/reoperation, superiority over microfracture for larger defects[4], [5], [6], [19]	Moderate–High	Strong (within licensed orthopaedic pathway)	Sponsor involvement; heterogeneity; superseded ACI generations[7]
Bone defect repair — MSCs in scaffolds	Systematic review (14 studies, 138 patients): healing in all cases, mild AEs, GRADE-assessed[11]	Low	Conditional / specialist setting	Small n, heterogeneity, few controls[11]
Periodontal/peri-implant reconstruction	128 RCTs: safe; equal or superior to conventional grafts for infrabony/furcation defects, ridge preservation, sinus augmentation[12]	Moderate	Conditional–Strong (dental specialist)	Variable comparators; PRO data limited[12]
Chronic/burn wound & dermal regeneration templates	Cohorts + trials: accelerated closure, fibrovascular ingrowth; established products (Integra, Matriderm, AlloDerm)[8], [9], [10]	Low–Moderate	Conditional (wound specialist)	Cost, heterogeneity, no full functional skin[9]
Tissue-engineered trachea/airway	Compassionate-use cases + animal models: high stenosis, infection, failed epithelialisation, deaths; associated misconduct[13], [14], [15]	Very low	Recommend against outside trials	Catastrophic AEs; retracted literature[13]
Systemic anti-ageing / senescence “rejuvenation” scaffolds	Animal/in-vitro only[1], [2], [3], [18]	Very low	Only in research	No human data

Across the field, publication bias and small samples are pervasive; preparations are non-standardised, limiting cross-study comparison.[20][21]



4. Patient selection and indications

– Who may benefit (evidence-based, referral-appropriate):

– Adults ~15–55 with symptomatic focal chondral defects (Outerbridge III–IV, ≥3 cm²) of the femoral condyle/trochlea, good alignment and stability — MACI/ACI via NHS/specialist orthopaedic pathway.[5][7]

– Patients with chronic non-healing or full-thickness/burn wounds — dermal templates via tissue-viability/plastics.[8][10]

– Periodontal/peri-implant or localised bone defects — via dental/maxillofacial specialists.[12][11]

– Clinical scenarios less appropriate for scaffold therapy: middle-aged cardiometabolic-risk patients or frail older adults seeking systemic longevity benefit — no scaffold therapy is indicated; benefit here is speculative.[1]

– Exclusion / high-risk: active local/systemic infection, uncontrolled inflammatory arthropathy, generalised osteoarthritis (poor cartilage-repair candidacy), immunosuppression, poorly controlled diabetes/vascular insufficiency (wound constructs), and any airway/organ construct outside a trial.[14][13]

– Regulatory/ethical status (UK): Cell-containing engineered constructs are Advanced Therapy Medicinal Products (ATMPs) regulated by the MHRA; hospital-exemption and ATMP routes, with NICE/NHS England as adoption gatekeepers. Autologous chondrocyte implantation is NICE-appraised and on established pathways. Marketed dermal templates are CE/UKCA devices. Bespoke cell-seeded scaffolds prepared or administered in an independent longevity clinic are off-label/experimental and, if ATMPs, may require MHRA authorisation and REC approval — such use should be within clinical-trial frameworks or formal registries with full informed consent.[22][23][24][7][25][26]



5. Assessment and baseline work-up

– History/examination: defect aetiology, duration and size; mechanical symptoms/joint alignment (cartilage); wound chronicity, perfusion and infection status; comorbidities (diabetes, smoking, vascular disease, immunosuppression); medications (immunosuppressants, anticoagulants, systemic steroids).

– Scoring tools: validated PROs — KOOS/IKDC/Tegner for knee cartilage; wound-area/healing metrics; periodontal indices.[5][6]

– Baseline investigations: targeted imaging (MRI with cartilage-sensitive sequences / T2 mapping for chondral defects; cross-sectional imaging for bone); FBC, glucose/HbA1c, CRP, renal/hepatic function; wound swab/vascular assessment where relevant.[6]

– Risk stratification: low risk = young, isolated focal defect, licensed pathway; moderate = comorbid/larger defect needing specialist MDT; high = infection, immunosuppression, systemic/organ constructs, or any use lacking human evidence.

– Baseline documentation: defect location/size, imaging, PRO scores, consent record, and — because longevity biomarkers are not validated endpoints for scaffolds — do not substitute biomarker change for clinical outcome.[1]



6. Dosing regimens and practical implementation

Scaffold therapies are procedural, not dose-titrated; “regimen” means construct type, cell seeding and surgical delivery.

– MACI/ACI (robust human data): two-stage — arthroscopic cartilage biopsy → ex-vivo chondrocyte expansion on a porcine collagen membrane → implantation into the debrided defect, followed by structured graded weightbearing/rehabilitation over months. Delivered only in specialist orthopaedic centres.[5][4]

– Dermal templates (established): single/staged application of acellular collagen–GAG or decellularised dermis (Integra, Matriderm, AlloDerm) with subsequent grafting; product choice by wound type, depth and periwound condition.[8][10]

– Bone/periodontal scaffolds: synthetic (β-TCP, calcium phosphate) or composite matrices ± bone-marrow aspirate/MSCs or growth factors, placed intra-operatively.[27][11][12]

– Requires caution (extrapolated / early-phase / preclinical): any cell-seeded or 3D-bioprinted “anti-senescence” construct, MSC-loaded rejuvenation scaffolds, and all airway/organ constructs — no established human dosing; research only.[1][3][14]



7. Monitoring, safety and follow-up

– Monitoring plan: clinical assessment of the treated site (pain, function, wound closure, signs of infection/graft failure); serial imaging (MRI defect fill/MOCART for cartilage); PRO re-measurement.[6]

– Timepoints: short-term wound/graft review (days–weeks for infection/dehiscence); medium-term functional review (3–12 months); long-term structural/PRO follow-up (annually; cartilage data extend to 10+ years).[19]

– Adverse effects:

– Common/mild: surgical-site pain, transient inflammation, effusion — largely procedure-related; overall favourable safety across cartilage RCTs and the MSC-scaffold review.[5][6][11]

– Cartilage-specific: graft hypertrophy/delamination, symptomatic failure/reoperation (~9% all-cause, ~7% progression to TKA at ≥10 yr).[19]

– Serious/rare: foreign-body reaction and immunogenic response to scaffold or degradation products; wound infection; and — for synthetic airway constructs — stenosis, graft collapse, infection and death.[28][14][15][13]

– Interactions/comorbidity: immunosuppression and poorly controlled diabetes impair integration/healing; smoking and vascular disease compromise wound constructs; anticoagulation affects operative planning.

– Actions for abnormal findings: infection → prompt antimicrobial ± explantation; graft failure/hypertrophy → orthopaedic review/revision; systemic reaction → cessation and specialist referral.

– Special populations: avoid in pregnancy/breastfeeding (no data); caution in frailty and extremes of age; account for renal/hepatic impairment in perioperative management. No scaffold therapy has established data in these groups for longevity indications.



8. Contraindications and cautions

– Absolute: active local or systemic infection at the site; known hypersensitivity to scaffold components (e.g. porcine collagen); use of synthetic tissue-engineered airways/whole organs outside an approved trial.[14][13]

– Relative / specialist advice required: immunosuppression, uncontrolled diabetes/vascular insufficiency, generalised osteoarthritis or malaligned/unstable joint (poor cartilage-repair candidate), significant comorbidity or frailty, pregnancy/breastfeeding.

– Harm likely to outweigh benefit with current evidence: any systemic anti-ageing scaffold use, and cell-seeded/bespoke constructs administered outside ATMP regulation and trial/registry oversight.[25][26][22]



9. Practical management scenarios

Scenario A — Middle-aged patient with multiple cardiometabolic risk factors requesting scaffold “regeneration” for longevity.

– Recommendation: Avoid / only in research (strong). No scaffold therapy has cardiometabolic or longevity outcome data.[1]

– Steps: confirm goals; explain absence of human evidence; redirect to evidence-based cardiometabolic risk reduction; offer scaffold therapy only for a specific licensed structural indication (e.g. a symptomatic chondral defect) via appropriate specialist referral. Document shared decision-making.

Scenario B — Older, frail patient with multimorbidity and osteoarthritis.

– Recommendation: Avoid cartilage cell-scaffold therapy (generalised OA and frailty predict poor outcomes; MACI is for focal defects in younger joints); restrict experimental anti-senescence scaffolds to research.[7][19]

– Steps: comprehensive geriatric/functional assessment; optimise conventional OA and frailty management; consider referral for standard interventions; avoid unproven, invasive constructs given the risk-benefit balance.

Scenario C — Patient under specialist care with a symptomatic focal knee chondral defect (≥3 cm²), considering scaffold therapy as adjunct.

– Recommendation: Offer/consider MACI via the established NHS/orthopaedic pathway (strong, evidence-based).[5][6][7]

– Steps: confirm defect size/location and joint stability on MRI; co-ordinate with the treating orthopaedic team (do not initiate independently); consent covering two-stage procedure, rehabilitation and ~9% reoperation / ~7% TKA risk at ≥10 years; structured rehabilitation; serial PRO and MRI follow-up; escalate for graft hypertrophy, failure or infection.[19]



10. Research gaps and future directions

– Key uncertainties: no linkage between scaffold interventions and validated ageing biomarkers or hard longevity/healthspan outcomes; heterogeneity and non-standardised construct/cell preparations preclude pooling; sparse RCT data beyond 5 years for newer ACI generations.[20][21][7]

– Priority questions: optimal cell source and seeding; vascularisation and epithelialisation of larger constructs; whether biomaterial modulation of cellular senescence translates from animal models to human benefit; standardised outcome sets and long-term safety registries.[29][30][2][3]

– Where practice should be limited to trials/registries: all cell-seeded bespoke constructs, 3D-bioprinted “anti-ageing” scaffolds, and any airway/organ engineering — conducted under MHRA/ATMP and REC oversight with informed consent, given prior serious harms and misconduct in the field.[13][14][25][22]

References

1. Materiobiology-Guided Regulation of Mesenchymal Stromal Cell Fate for Aging-Related Diseases: From Basic Parameter Design to Clinical Application. Feng Y, Qiu Y, Zhang S, et al. Bioactive Materials. 2026;61:577-600. doi:10.1016/j.bioactmat.2026.02.034.
2. Mesenchymal Stem Cell Senescence and Biomaterial-Based Next-Generation Rejuvenation Strategy. Zhang Y, Judeh R, Aravind S, Zreiqat H, Lu Z. Tissue Engineering. Part B, Reviews. 2025;:19373341251372962. doi:10.1177/19373341251372962.
3. Three-Dimensional Bioprinted Scaffolds Loaded With Multifunctional Magnesium-Based Metal-Organic Frameworks Improve the Senescence Microenvironment Prompting Aged Bone Defect Repair. Sun X, Xu X, Zhao X, et al. ACS Nano. 2025;19(24):22141-22162. doi:10.1021/acsnano.5c03023.
4. Matrix-Applied Characterized Autologous Cultured Chondrocytes Versus Microfracture: Five-Year Follow-Up of a Prospective Randomized Trial. Brittberg M, Recker D, Ilgenfritz J, Saris DBF. The American Journal of Sports Medicine. 2018;46(6):1343-1351. doi:10.1177/0363546518756976.
5. Matrix-Applied Characterized Autologous Cultured Chondrocytes Versus Microfracture: Two-Year Follow-Up of a Prospective Randomized Trial. Saris D, Price A, Widuchowski W, et al. The American Journal of Sports Medicine. 2014;42(6):1384-94. doi:10.1177/0363546514528093.
6. Arthroscopic Matrix-Assisted Autologous Chondrocyte Transplantation Versus Microfracture: A 6-Year Follow-Up of a Prospective Randomized Trial. Ibarra C, Villalobos E, Madrazo-Ibarra A, et al. The American Journal of Sports Medicine. 2021;49(8):2165-2176. doi:10.1177/03635465211010487.
7. Autologous Chondrocyte Implantation in the Knee: Systematic Review and Economic Evaluation. Mistry H, Connock M, Pink J, et al. Health Technology Assessment (Winchester, England). 2017;21(6):1-294. doi:10.3310/hta21060.
8. The Role of Adipose‐Derived Stem Cells, Dermal Regenerative Templates, and Platelet‐Rich Plasma in Tissue Engineering‐Based Treatments of Chronic Skin Wounds. Conese M, Annacontini L, Carbone A, et al. Stem Cells International. 2020;2020:7056261. doi:10.1155/2020/7056261.
9. Regenerative Medicine: Postnatal Approaches. Tam PKH, Wong KKY, Atala A, et al. The Lancet. Child & Adolescent Health. 2022;6(9):654-666. doi:10.1016/S2352-4642(22)00193-6.
10. Wound Care-Part II: Tissue-Engineered Skin Substitutes and Other Advanced Wound Therapies. Haxho F, Lytvyn Y, Shelley AJ, et al. Journal of the American Academy of Dermatology. 2026;95(3):605-620. doi:10.1016/j.jaad.2025.06.045.
11. Bone Regeneration With Mesenchymal Stem Cells in Scaffolds: Systematic Review of Human Clinical Trials. Theodosaki AM, Tzemi M, Galanis N, et al. Stem Cell Reviews and Reports. 2024;20(4):938-966. doi:10.1007/s12015-024-10696-5.
12. Clinical and patient‐reported outcomes of tissue engineering strategies for periodontal and peri‐implant reconstruction. Tavelli L, Barootchi S, Rasperini G, Giannobile WV. Periodontology 2000. 2023;91(1):217-269. doi:10.1111/prd.12446.
13. State of the Art of Clinical Applications of Tissue Engineering in 2021. Paternoster JL, Vranckx JJ. Tissue Engineering. Part B, Reviews. 2022;28(3):592-612. doi:10.1089/ten.TEB.2021.0017.
14. Factors Influencing Poor Outcomes in Synthetic Tissue-Engineered Tracheal Replacement. Pepper V, Best CA, Buckley K, et al. Otolaryngology–Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery. 2019;161(3):458-467. doi:10.1177/0194599819844754.
15. Deconstructing Tissue Engineered Trachea: Assessing the Role of Synthetic Scaffolds, Segmental Replacement and Cell Seeding on Graft Performance. Dharmadhikari S, Liu L, Shontz K, et al. Acta Biomaterialia. 2020;102:181-191. doi:10.1016/j.actbio.2019.11.008.
16. Scaffolding Strategies for Tissue Engineering and Regenerative Medicine Applications. Pina S, Ribeiro VP, Marques CF, et al. Materials (Basel, Switzerland). 2019;12(11):E1824. doi:10.3390/ma12111824.
17. The Great Harmony in Translational Medicine: Biomaterials and Stem Cells. Erten E, Arslan YE. Advances in Experimental Medicine and Biology. 2018;1119:21-39. doi:10.1007/5584_2018_231.
18. Engineering Biomaterial-Mediated Delivery for Osteoarthritis: Targeting Aging Mechanisms to Reestablish Joint Homeostasis. Tang X, Liu S, Liu H, et al. Nanoscale. 2026;18(32):16978-17004. doi:10.1039/d6nr01324d.
19. Minimum 10-Year Outcomes of Matrix-Induced Autologous Chondrocyte Implantation in the Knee: A Systematic Review. Wang AS, Nagelli CV, Lamba A, et al. The American Journal of Sports Medicine. 2024;52(9):2407-2414. doi:10.1177/03635465231205309.
20. Nonoperative and Operative Soft-Tissue and Cartilage Regeneration and Orthopaedic Biologics of the Knee: An Orthoregeneration Network (ON) Foundation Review. Knapik DM, Evuarherhe A, Frank RM, et al. Arthroscopy : The Journal of Arthroscopic & Related Surgery : Official Publication of the Arthroscopy Association of North America and the International Arthroscopy Association. 2021;37(8):2704-2721. doi:10.1016/j.arthro.2021.04.002.
21. Nonoperative and Operative Soft-Tissue, Cartilage, and Bony Regeneration and Orthopaedic Biologics of the Shoulder: An Orthoregeneration Network (ON) Foundation Review. Condron NB, Kester BS, Tokish JM, et al. Arthroscopy : The Journal of Arthroscopic & Related Surgery : Official Publication of the Arthroscopy Association of North America and the International Arthroscopy Association. 2021;37(10):3200-3218. doi:10.1016/j.arthro.2021.06.033.
22. Opening the Gateways to Market and Adoption of Regenerative Medicine? The UK Case in Context. Faulkner A. Regenerative Medicine. 2016;11(3):321-30. doi:10.2217/rme-2015-0046.
23. Recent advancements in cartilage tissue engineering innovation and translation. Nordberg RC, Bielajew BJ, Takahashi T, et al. Nature Reviews. Rheumatology. 2024;20(6):323-346. doi:10.1038/s41584-024-01118-4.
24. A Worldwide Overview of Regulatory Frameworks for Tissue-Based Products. Oberweis CV, Marchal JA, López-Ruiz E, Gálvez-Martín P. Tissue Engineering. Part B, Reviews. 2020;26(2):181-196. doi:10.1089/ten.TEB.2019.0315.
25. The Ethical Implications of Tissue Engineering for Regenerative Purposes: A Systematic Review. de Kanter AJ, Jongsma KR, Verhaar MC, Bredenoord AL. Tissue Engineering. Part B, Reviews. 2023;29(2):167-187. doi:10.1089/ten.TEB.2022.0033.
26. Stem Cells and Tissue Engineering in Medical Practice: Ethical and Regulatory Policies. Sharma R. Current Drug Targets. 2019;20(4):388-398. doi:10.2174/1389450119666180831095830.
27. Nonoperative and Operative Soft-Tissue and Cartilage Regeneration and Orthopaedic Biologics of the Foot and Ankle: An Orthoregeneration Network Foundation Review. Danilkowicz R, Murawski C, Pellegrini M, et al. Arthroscopy : The Journal of Arthroscopic & Related Surgery : Official Publication of the Arthroscopy Association of North America and the International Arthroscopy Association. 2022;38(7):2350-2358. doi:10.1016/j.arthro.2022.04.018.
28. The Immune Reaction and Degradation Fate of Scaffold in Cartilage/Bone Tissue Engineering. Yang D, Xiao J, Wang B, et al. Materials Science & Engineering. C, Materials for Biological Applications. 2019;104:109927. doi:10.1016/j.msec.2019.109927.
29. Advances and Challenges in Tracheal Epithelium Regeneration: Insights Into Tissue Engineering Approaches. Gadalla D, Kennedy MM, Lott DG. Cells, Tissues, Organs. 2026;215(1):56-80. doi:10.1159/000545132.
30. Development and Clinical Translation of Tubular Constructs for Tracheal Tissue Engineering: A Review. Soriano L, Khalid T, Whelan D, et al. European Respiratory Review : An Official Journal of the European Respiratory Society. 2021;30(162):210154. doi:10.1183/16000617.0154-2021.